SGLT2 Inhibitors Tied to Lower Kidney Cancer Risk - Takeaways - MDSpire

SGLT2 Inhibitors Tied to Lower Kidney Cancer Risk

  • By

  • Andrea Surnit

  • June 9, 2026

Share

  • 1

    SGLT2 inhibitors are associated with a lower incidence of kidney cancer compared to DPP-4 inhibitors in patients with type 2 diabetes.

  • 2

    The study involved 57,103 users of SGLT2 inhibitors and 57,103 users of DPP-4 inhibitors, with a follow-up of approximately 3.5 years.

  • 3

    SGLT2 inhibitor users had a 40% lower hazard of kidney cancer, with an incidence rate of 18.9 cases per 100,000 person-years.

  • 4

    The findings suggest potential mechanisms for reduced kidney cancer risk, but these were not directly tested in the study.

  • 5

    Limitations include observational design, short follow-up, and lack of individual agent data, affecting generalizability and potential confounding.

Original Source(s)

SGLT2 Inhibitors Tied to Lower Kidney Cancer Risk

  • by Andrea Surnit

  • June 9, 2026

Related Content

Targeted therapy in thyroid cancer: molecular alterations and clinical management

Semaglutide Tied to Aging Clocks in HIV

A posthoc analysis of a phase 2b trial found favorable changes in DNA methylation–based aging biomarkers among patients with human immunodeficiency virus–associated lipohypertrophy.

Birthweight, Childhood BMI: What Drives the Link?

Mendelian randomization analyses linked higher birthweight with greater mid-childhood height but the connection could reflect genetic factors related to skeletal growth.